IMMATICS demonstrated the clinical activity of IMA402 PRAME bispecific therapy and IMA203CD8 PRAME cell therapy in advanced solid tumors through two oral presentations at the 2026 ESMO annual meeting.

Zhitongcaijing · 3d ago
IMMATICS demonstrated the clinical activity of IMA402 PRAME bispecific therapy and IMA203CD8 PRAME cell therapy in advanced solid tumors through two oral presentations at the 2026 ESMO annual meeting.